Hormone Evaluation in a 43-Year-Old Menstruating Woman
No hormonal therapy is indicated, but the borderline-elevated TSH warrants repeat thyroid testing in 4–8 weeks, and the elevated estradiol with suppressed gonadotropins suggests mid-cycle timing rather than pathology.
Interpretation of Hormone Results
Your patient's hormone profile is consistent with normal reproductive physiology in the perimenopausal transition, not a pathologic state requiring intervention:
Estradiol and Gonadotropins
The estradiol of 703 pmol/L (~191 pg/mL) with low-normal LH (2.5) and FSH (3.0) indicates either periovulatory or mid-luteal phase timing. Elevated estradiol physiologically suppresses LH and FSH through negative feedback, explaining the "low" gonadotropins 1.
In women aged 43–50 years who continue cycling, estradiol levels can be paradoxically elevated compared to younger women, particularly in the follicular and periovulatory phases, even as FSH begins to rise 2. Your patient's FSH of 3.0 is actually lower than expected for age 43, when mean FSH typically begins climbing above 10 IU/L by the mid-follicular phase 3, 2.
Progesterone of 32.4 nmol/L (~10 ng/mL) confirms ovulation occurred in this cycle, indicating intact corpus luteum function 2.
Thyroid Function
TSH of 4.01 mIU/L sits at the upper limit of normal (most labs use 0.4–4.5 range). While thyroid dysfunction is a recognized cause of abnormal uterine bleeding 4, your patient is still menstruating regularly, making clinically significant hypothyroidism unlikely.
Recheck TSH in 4–8 weeks to confirm stability. If persistently >4.5 or if she develops menstrual irregularity, measure free T4 and consider subclinical hypothyroidism 5, 4.
Testosterone
- Testosterone 0.6 nmol/L (~17 ng/dL) is normal for a premenopausal woman and does not suggest hyperandrogenism 4.
Why No Intervention Is Needed
Hormonal Therapy Is Not Indicated
Guidelines do not support measuring estradiol, progesterone, LH, or FSH to guide hormone therapy decisions in menstruating women 6. Symptoms and shared decision-making—not laboratory values—drive hormone therapy 6.
Your patient is ovulating normally (evidenced by progesterone 32.4) and has no reported symptoms (hot flashes, vaginal atrophy, mood changes) that would warrant estrogen or progesterone supplementation 7.
The elevated estradiol is physiologic, not pathologic. Perimenopausal women commonly exhibit hyperestrogenism alongside rising FSH, a pattern associated with shortened follicular phases but preserved ovulation 2, 8.
Common Pitfalls to Avoid
Do not interpret "low" LH/FSH as pituitary failure when estradiol is high. Elevated estradiol suppresses gonadotropins via negative feedback; this is normal physiology, not hypogonadotropic hypogonadism 1.
Do not order repeat sex-hormone panels unless menstrual patterns change. Single-timepoint hormone levels are notoriously difficult to interpret due to cyclical variation 6. FSH measured in the early follicular phase (cycle days 2–5) is the only timing with clinical utility for assessing ovarian reserve 5.
Avoid attributing vague symptoms to "hormone imbalance" based on these results. If she develops oligomenorrhea (cycles >35 days apart) or amenorrhea lasting ≥3 months, then reassess with early-follicular FSH, prolactin, and TSH 5, 4.
When to Reassess
If menses become irregular or cease: Repeat pregnancy test, TSH, prolactin, and early-follicular FSH/LH 5, 4.
If TSH remains >4.5 on repeat testing: Measure free T4 and consider levothyroxine if free T4 is low-normal or if she develops symptoms 5.
If she desires fertility assessment: Early-follicular FSH (days 2–5) and anti-Müllerian hormone (AMH) provide ovarian reserve information, though at age 43 diminished reserve is expected 2, 8.